ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026
Early administration of ivabradine in patients with acute anterior ST-elevation myocardial infarction: a prospective, randomized, open-label study on in-hospital and short-term major adverse cardiac events and left ventricular function.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElevated heart rate (HR) in acute anterior ST-elevation myocardial infarction (STEMI) increases myocardial oxygen demand and limits perfusion, worsening outcomes. Ivabradine selectively reduces HR without negative inotropy. This open-label randomized controlled study investigates the efficacy and safety of early ivabradine administration in patients with acute anterior STEMI.
methodsThis randomized controlled prospective study included 300 patients with acute anterior STEMI (sinus rhythm, HR > 70 bpm) at Ain Shams University hospitals. Patients were randomized 1:1 to receive either standard beta-blocker therapy plus ivabradine (Ivabradine group, n = 150) or standard beta-blocker therapy alone (Control group, n = 150). Echocardiographic assessors and clinical event adjudicators were blinded to treatment allocation. Primary outcomes were changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), HR, cardiac biomarkers (CK-MB, Troponin), and the incidence of major adverse cardiac events (MACE) at 3-month follow-up. Procedural variables (door-to-balloon time, final TIMI flow, myocardial blush grade, no-reflow phenomenon), Killip class, arrhythmic events, and guideline-directed medical therapy use were documented.
resultsBaseline demographic, angiographic, and medical therapy characteristics were similar between groups. At 3 months, the Ivabradine group demonstrated a significantly greater improvement in LVEF compared to controls (mean ± SD: 51.96 ± 6.09% vs. 49.79 ± 4.47%, p < 0.001). LVEDV significantly decreased in the Ivabradine group (from 101.44 ± 13.84 mL to 83.65 ± 8.76 mL) but increased in the control group (from 100.49 ± 12.73 mL to 120.67 ± 10.15 mL) (p < 0.001 for final LVEDV between groups). Final HR was significantly lower in the Ivabradine group (62.31 ± 1.79 vs. 76.13 ± 3.54 bpm, p < 0.001). The incidence of heart failure hospitalization (1.3% vs. 11.3%, p < 0.001) and total MACE (12.7% vs. 32.0%, p < 0.001) were significantly reduced in the Ivabradine group. No significant differences were observed in no-reflow rates (12.0% vs. 14.7%, p = 0.491) or ventricular arrhythmias (2.7% vs. 4.0%, p = 0.523) between groups.
conclusionEarly administration of ivabradine in patients with acute anterior STEMI and elevated HR without cardiogenic shock was associated with better heart-rate control and favorable short-term echocardiographic outcomes, while the clinical outcome findings require confirmation in prospectively registered, adequately powered multicenter trials. These findings apply to Killip class I-III patients; Killip class IV patients (cardiogenic shock) were excluded from this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.